Athira Pharma, Inc. (NASDAQ:LONA) Receives $17.33 Consensus Price Target from Brokerages

Athira Pharma, Inc. (NASDAQ:LONA) has been assigned an average rating of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $17.3333.

LONA has been the subject of several analyst reports. Citizens Jmp decreased their price target on shares of Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating for the company in a research report on Monday, August 17th. Mizuho cut their price objective on shares of Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a research note on Friday, August 7th. Piper Sandler initiated coverage on shares of Athira Pharma in a research report on Wednesday, May 27th. They set an “overweight” rating and a $20.00 target price for the company. Finally, Wall Street Zen raised shares of Athira Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th.

Athira Pharma Price Performance

Shares of NASDAQ LONA opened at $7.56 on Friday. The stock has a market capitalization of $70.99 million, a P/E ratio of -1.80 and a beta of 2.05. Athira Pharma has a 1-year low of $3.52 and a 1-year high of $14.21. The business has a fifty day moving average price of $8.04 and a 200 day moving average price of $8.60.

Athira Pharma (NASDAQ:LONA) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.20). As a group, equities research analysts anticipate that Athira Pharma will post -2.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in LONA. Commodore Capital LP acquired a new stake in Athira Pharma in the fourth quarter worth about $3,515,000. Seven Fleet Capital Management LP acquired a new position in shares of Athira Pharma during the fourth quarter valued at about $969,000. Spruce Street Capital LP acquired a new position in shares of Athira Pharma during the fourth quarter valued at about $2,980,000. Perceptive Advisors LLC raised its position in shares of Athira Pharma by 244.1% in the 4th quarter. Perceptive Advisors LLC now owns 1,859,322 shares of the company’s stock valued at $14,075,000 after purchasing an additional 1,319,026 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in shares of Athira Pharma in the 4th quarter valued at approximately $2,456,000. 57.12% of the stock is owned by institutional investors and hedge funds.

Athira Pharma Company Profile

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.